Pharma BD Deal Intelligence
Pfizer acquiring two Baxter vaccines for $635M; the two products had combined expected 2014 sales of $300 million and are sold primarily in European markets.
BioPharma-Reporter highlighted the strategic logic of Pfizer absorbing Baxter's Orth, Austria vaccine plant as ex-US infrastructure to support both NeisVac-C…
BioPharma Dive reported deal close on Dec 2, 2014, framing the $635M acquisition as Pfizer adding 'value, scale, and depth' to its Prevnar-led vaccine…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Pfizer agreed to acquire Baxter's commercial vaccines portfolio—NeisVac-C meningococcal vaccine and FSME-IMMUN/TicoVac tick-borne encephalitis vaccine—for $635M cash, complementing its Prevnar franchise. Closed December 1, 2014; aligned with Baxter's preparation to spin off Baxalta.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Baxter International Inc. (commercial vaccines portfolio) (this deal) | 2014 | $635M | 77 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2014 deals · Pfizer Inc. deals · Vaccines deals